Loading…

Single oral dose pharmacokinetics of the two main components of pristinamycin in humans

A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1990-04, Vol.25 (4), p.651-656
Main Authors: Koechlin, Christophe, Kempf, Jean-François, Jehl, François, Monteil, Henri
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253
cites
container_end_page 656
container_issue 4
container_start_page 651
container_title Journal of antimicrobial chemotherapy
container_volume 25
creator Koechlin, Christophe
Kempf, Jean-François
Jehl, François
Monteil, Henri
description A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods.
doi_str_mv 10.1093/jac/25.4.651
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79818848</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79818848</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhS0EKtOBHVukbGDVTK-fsZfQForUgsRDIDbWjeMwaRN7amcE_fe4zKhdYlny4js60vlMyAsKKwqGH1-hO2ZyJVZK0kdkQYWCmoGhj8kCOMi6EZI_JYc5XwGAkkofkANGKZMCFuT7lyH8Gn0VE45VF7OvNmtME7p4PQQ_Dy5Xsa_mta_m37GacAiVi9MmBh_mf2iThjwPAadbV1i56-2EIT8jT3ocs3--f5fk27uzryfn9cWn9x9O3lzUjgPMtXDQUGaYRtd3ihkhUOm-A2NUrx1ruVaOCt9K12ra-g4k7zqkUjCveJnAl-T1rneT4s3W59lOQ3Z-HDH4uM22MZpqLfR_g1Q2XPFyluRoF3Qp5px8b8vECdOtpWDvhNsi3DJphS3CS_zlvnfbTr67D-8NF_5qzzE7HPuEwQ35odOI8iv6bki9yxWd_s89x3RtVcMbac9__LSXpx_fgjml9jP_C-1Kl8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15736333</pqid></control><display><type>article</type><title>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</title><source>Oxford University Press Archive</source><creator>Koechlin, Christophe ; Kempf, Jean-François ; Jehl, François ; Monteil, Henri</creator><creatorcontrib>Koechlin, Christophe ; Kempf, Jean-François ; Jehl, François ; Monteil, Henri</creatorcontrib><description>A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/25.4.651</identifier><identifier>PMID: 2112540</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Chromatography, High Pressure Liquid ; Female ; Half-Life ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Virginiamycin - administration &amp; dosage ; Virginiamycin - blood ; Virginiamycin - pharmacokinetics</subject><ispartof>Journal of antimicrobial chemotherapy, 1990-04, Vol.25 (4), p.651-656</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19400085$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2112540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koechlin, Christophe</creatorcontrib><creatorcontrib>Kempf, Jean-François</creatorcontrib><creatorcontrib>Jehl, François</creatorcontrib><creatorcontrib>Monteil, Henri</creatorcontrib><title>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Virginiamycin - administration &amp; dosage</subject><subject>Virginiamycin - blood</subject><subject>Virginiamycin - pharmacokinetics</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><recordid>eNqFkUtv1DAUhS0EKtOBHVukbGDVTK-fsZfQForUgsRDIDbWjeMwaRN7amcE_fe4zKhdYlny4js60vlMyAsKKwqGH1-hO2ZyJVZK0kdkQYWCmoGhj8kCOMi6EZI_JYc5XwGAkkofkANGKZMCFuT7lyH8Gn0VE45VF7OvNmtME7p4PQQ_Dy5Xsa_mta_m37GacAiVi9MmBh_mf2iThjwPAadbV1i56-2EIT8jT3ocs3--f5fk27uzryfn9cWn9x9O3lzUjgPMtXDQUGaYRtd3ihkhUOm-A2NUrx1ruVaOCt9K12ra-g4k7zqkUjCveJnAl-T1rneT4s3W59lOQ3Z-HDH4uM22MZpqLfR_g1Q2XPFyluRoF3Qp5px8b8vECdOtpWDvhNsi3DJphS3CS_zlvnfbTr67D-8NF_5qzzE7HPuEwQ35odOI8iv6bki9yxWd_s89x3RtVcMbac9__LSXpx_fgjml9jP_C-1Kl8w</recordid><startdate>199004</startdate><enddate>199004</enddate><creator>Koechlin, Christophe</creator><creator>Kempf, Jean-François</creator><creator>Jehl, François</creator><creator>Monteil, Henri</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>199004</creationdate><title>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</title><author>Koechlin, Christophe ; Kempf, Jean-François ; Jehl, François ; Monteil, Henri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Virginiamycin - administration &amp; dosage</topic><topic>Virginiamycin - blood</topic><topic>Virginiamycin - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koechlin, Christophe</creatorcontrib><creatorcontrib>Kempf, Jean-François</creatorcontrib><creatorcontrib>Jehl, François</creatorcontrib><creatorcontrib>Monteil, Henri</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koechlin, Christophe</au><au>Kempf, Jean-François</au><au>Jehl, François</au><au>Monteil, Henri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1990-04</date><risdate>1990</risdate><volume>25</volume><issue>4</issue><spage>651</spage><epage>656</epage><pages>651-656</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>2112540</pmid><doi>10.1093/jac/25.4.651</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 1990-04, Vol.25 (4), p.651-656
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_79818848
source Oxford University Press Archive
subjects Administration, Oral
Adult
Aged
Aged, 80 and over
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Chromatography, High Pressure Liquid
Female
Half-Life
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Virginiamycin - administration & dosage
Virginiamycin - blood
Virginiamycin - pharmacokinetics
title Single oral dose pharmacokinetics of the two main components of pristinamycin in humans
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A10%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single%20oral%20dose%20pharmacokinetics%20of%20the%20two%20main%20components%20of%20pristinamycin%20in%20humans&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Koechlin,%20Christophe&rft.date=1990-04&rft.volume=25&rft.issue=4&rft.spage=651&rft.epage=656&rft.pages=651-656&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/25.4.651&rft_dat=%3Cproquest_cross%3E79818848%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15736333&rft_id=info:pmid/2112540&rfr_iscdi=true